GlassScriptPhysician profile
Emanuela Cimpeanu
NPI 1760914857
$1,014.08
in general payments reported to CMS, 2019-2025
14 companies · $99.99 in 2025
The $99.99 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $330 · 2023: $488 · 2024: $95.84 · 2025: $99.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.88 |
| Education | $288.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $272.65 | 2022-2023 | Nplate |
| E.R. Squibb & Sons, L.L.C. | $100.66 | 2022-2023 | Opdivo |
| Janssen Biotech, INC. | $99.99 | 2025 | Erleada |
| Exelixis INC. | $99.99 | 2023 | |
| Tempus Ai, INC | $95.84 | 2024 | |
| Seagen INC. | $89.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.00 | 2023 | |
| Array Biopharma INC | $35.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.97 | 2023 | Ninlaro |
| Regeneron Healthcare Solutions, INC. | $27.90 | 2023 | Libtayo |
| Kyowa Kirin, INC. | $24.97 | 2023 | Poteligeo |
| Myovant Sciences INC. | $23.64 | 2022 | |
| Celgene Corporation | $21.28 | 2022 | |
| Glaxosmithkline, LLC. | $19.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emanuela Cimpeanu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.